中國同輻(01763.HK)附屬與關連方組兩間醫藥中心合營
中國同輻(01763.HK)公布關連交易,公司之非全資附屬原子高科與新原實業訂立貴陽合營協議,雙方同意於中國成立貴陽合營公司;原子高科與新疆礦冶局亦訂立新疆合營協議,雙方同意於中國成立新疆合營公司。
根據貴陽合營協議,貴陽合營公司之註冊資本應為3,250萬元人民幣(下同)。原子高科將以現金向貴陽合營公司注資2,762.5萬元人民幣,佔股權85%。根據新疆合營協議之條款,新疆合營公司之註冊資本應為3,200萬元。原子高科將以現金向新疆合營公司注資2,432萬元,佔股權76%。
貴陽合營公司將作為貴州區域的醫藥中心,主要從事即時標記系列藥物的生產和銷售,正電子藥物(18F-FDG)的生產和銷售,其他放射性藥品銷售及相關技術諮詢。新疆合營公司將作為新疆區域的醫藥中心,主要從事即時標記系列藥物的生產和銷售,正電子藥物(18F-FDG)的生產和銷售,其他放射性藥品銷售及相關技術諮詢和服務。
中核集團通過其全資附屬中國鈾業持有新原實業100%的股權。新疆礦冶局則為中核集團通過其全資附屬中國鈾業直接控制和管理的事業單位。並構成公司關連交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.